Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction

European Journal of Clinical Pharmacology

Volumn 64, Issue 12, 2008, Pages 1147-1161

  Verbeeck, Roger K ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Drug clearance; Drug dosage adjustment; Hepatic dysfunction; Liver disease; Pharmacokinetics

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAFFEINE; CARVEDILOL; CLOMETHIAZOLE; CYTOCHROME P450; DIURETIC AGENT; ERYTHROMYCIN; GALACTOSE; LABETALOL; METOPROLOL; MIDAZOLAM; MORPHINE; NARCOTIC ANALGESIC AGENT; NIFEDIPINE; NISOLDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; PENTAZOCINE; PETHIDINE; PHENAZONE; PROPRANOLOL; SORBITOL; VERAPAMIL;

BILIARY EXCRETION; DOSE CALCULATION; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG PROTEIN BINDING; ENZYME ACTIVITY; GLUCURONIDATION; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER FUNCTION TEST; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT; URINARY EXCRETION;

CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LIVER; LIVER DISEASES; METABOLIC CLEARANCE RATE; METABOLIC DETOXICATION, DRUG; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS;

EID: 57049161412     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-008-0553-z     Document Type: Review

References (142)

1. SM Pond TN Tozer 1984 First-pass elimination: basic concepts and clinical consequences Clin Pharmacokinet 9 1 15
2. PB Danielson 2002 The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans Curr Drug Metab 3 561 597
3. MB Fisher MF Paine TJ Strelevitz SA Wrighton 2001 The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism Drug Metab Rev 33 273 297
4. DJ Morgan AJ McLean 1995 Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease-an update Clin Pharmacokinet 29 370 391
5. J Reichen 1999 The role of the sinusoidal endothelium in liver function News Physiol Sci 14 117 121
6. Giacomini KM, Sigiyama Y (2006) Membrane transporters and drug response. In: Brunton LL, Lazo JS, Parker KL (eds) Goodman & Gilman's the pharmacological basis of therapeutics, 11th edn. McGraw-Hill, New York, pp 41-70
7. P Chandra KLR Brouwer 2004 The complexities of hepatic transport: current knowledge and emerging concepts Pharm Res 21 719 735
8. DG Le Couteur R Fraser S Hilmer LP Rivory AJ McLean 2005 The hepatic sinusoid in aging and cirrhosis: effects on hepatic substrate disposition and drug clearance Clin Pharmacokinet 44 187 200
9. M Traumer PJ Meier JL Boyer 1999 Molecular regulation of hepatocellular transport systems in cholestatsis J Hepatol 31 165 178
10. M Rowland LZ Benet GG Graham 1973 Clearance concepts in pharmacokinetics J Pharmacokinet Biopharm 1 123 136
11. GR Wilkinson 1987 Clearance approaches in pharmacology Pharmacol Rev 39 1 47
12. EMM Quigley 1996 Gastrointestinal dysfunction in liver disease and portal hypertension: gut-liver interactions revisited Dig Dis Sci 41 557 563
13. MJ Zuckerman IS Menzies H Ho GG Gregory NA Casner RS Crane JA Hernandez 2004 Assessment of intestinal permeability and absorption in cirrhotic patients with ascites using combined sugar probes Dig Dis Sci 49 621 626
14. TF Blaschke PC Rubin 1979 Hepatic first-pass metabolism in liver disease Clin Pharmacokinet 4 423 432
15. YK Tam 1993 Individual variation in first-pass metabolism Clin Pharmacokinet 25 300 328
16. Wilkinson GR (1980) Influence of liver disease on pharmacokinetics. In: Evans WE, Schentag JJ, Jusko WJ (eds) Applied pharmacokinetics-principles of therapeutic drug monitoring. Applied Therapeutics, San Francisco, pp 19-41
17. PJ Pentikäinen PJ Neuvonen KG Jotell 1980 Pharmacokinetics of chlormethiazole in healthy volunteers and patients with cirrhosis of the liver Eur J Clin Pharmacol 17 275 284
18. G Neugebauer M Gabor K Reiff 1988 Pharmacokinetics and bioavailability of carvedilol in patients with liver cirrhosis Drugs 36 Suppl 6 148 154
19. M Homeida L Jackson CJC Roberts 1978 Decreased first-pass metabolism of labetalol in chronic liver disease Br Med J 2 1048 1050
20. EA Neal PJ Meffin PB Gregory TF Blaschke 1979 Enhanced bioavailability and decreased clearance of analgesics in patients with cirrhosis Gastroenterology 77 96 102
21. Regårdh C-G, Jordö L, Lundborg P, Olsson R, Rönn O (1981) Pharmacokinetics of metoprolol in patients with hepatic cirrhosis. Clin Pharmacokinet 6:375-388
22. PJ Pentikäinen L Välisalmi JL Himberg C Crevoisier 1989 Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects J Clin Pharmacol 29 272 277
23. J Hasselström S Eriksson A Persson A Rane JO Svensson J Säwe 1990 The metabolism and bioavailability of morphine in patients with severe liver cirrhosis Br J Clin Pharmacol 29 289 297
24. CH Kleinbloesem J van Harten JPH Wilson M Danhof P van Brummelen DD Breimer 1986 Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration Clin Pharmacol Ther 40 21 28
25. J van Harten P van Brummelen JHP Wilson MTM Lodewijks DD Breimer 1988 Nisoldipine: kinetics and effects on blood pressure and heart rate in patients with liver cirrhosis after intravenous and oral administration Eur J Clin Pharmacol 34 387 394
26. RA Branch DM Kornhauser DG Shand GR Wilkinson AJJ Wood 1977 Biological determinants of propranolol disposition in normal subjects and patients with cirrhosis Br J Clin Pharmacol 4 630P
27. A Somogyi M Albrecht G Kliems K Schafer M Eichelbaum 1981 Pharmacokinetics, bioavailability and ECH response in patients with liver cirrhosis Br J Clin Pharmacol 12 51 60
28. N Chalasani JC Gorski NH Patel SD Hall RE Galinsky 2001 Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: effects of transjugular intrahepatic portosystemic shunts Hepatology 34 1103 1108
29. JC Gorski DR Jones BD Haehner-Daniels MA Hamman EM O'Mara Jr SD Hall 1998 The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin Clin Pharmacol Ther 64 133 143
30. MacKichan JJ (2006) Influence of protein binding and use of unbound (free) drug concentrations. In: Burton ME, Shaw LM, Schentag JJ, Evans WE (eds) Applied pharmacokinetics & pharmacodynamics-principles of therapeutic drug monitoring. Lippincott Williams & Wilkins, Philadelphia, pp 82-120
31. TF Blaschke 1977 Protein binding and kinetics of drugs in liver disease Clin Pharmacokinet 2 32 44
32. M el Touny M el Guinaidy M Abdel Bary L Osman MS Sabbour 1992 Pharmacokinetics of cefodizime in patients with liver cirrhosis and ascites Chemotherapy 38 201 205
33. RL Williams RA Upton JP Cello RM Jones M Blitstein J Kelly D Nierenburg 1984 Naproxen disposition in patients with alcoholic cirrhosis Eur J Clin Pharmacol 27 291 296
34. Tozer TN (1986) Concepts basic to pharmacokinetics. In: Rowland M, Tucker G (eds) Pharmacokinetics-theory and practice. Pergamon Press, Oxford, pp 29-51
35. F Delcò L Tchambaz R Schlienger J Drewe S Krähenbühl 2005 Dosage adjustment in patients with liver disease Drug Saf 28 529 545
36. L Liu KS Pang 2004 The roles of transporters and enzymes in hepatic drug processing Drug Metab Disp 33 1 7
37. DJ Morgan AJ McLean 1991 Therapeutic implications of impaired hepatic oxygen diffusion in chronic liver disease Hepatology 14 1280 1282
38. J George M Murray K Byth 1995 Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease Hepatology 21 20 128
39. J George C Liddle M Murray 1995 Pre-translational regulation of cytochrome P450 genes is responsible for disease-specific changes of individual P450 enzymes among patients with cirrhosis Biochem Pharmacol 49 873 881
40. V Furlan S Demirdjian O Bourdon 1999 Glucuronidation of drugs by hepatic microsomes derived from healthy and cirrhotic human livers J Pharmacol Exp Ther 289 1169 1175
41. J-P Villeneuve V Pichette 2004 Cytochrome P450 and liver diseases Curr Drug Metab 5 273 282
42. RH Elbekai HM Korashy OS El-Kadi 2000 The effect of liver cirrhosis on the regulation and expression of drug metabolising enzymes Curr Drug Metab 5 157 167
43. A Adedoyin PA Arns WO Richards GR Wilkinson RA Branch 1998 Selective effect of liver disease on the activities of specific metabolizing enzymes: investigation of cytochromes P450 2C19 and 2D6 Clin Pharmacol Ther 64 8 17
44. RA Branch 1998 Drugs in liver disease Clin Pharmacol Ther 64 462 465
45. RF Frye NK Zgheib GR Matzke D Chaves-Gnecco M Rabinovitz OS Shaikh RA Branch 2006 Liver disease selectively modulates cytochrome P450-mediated metabolism Clin Pharmacol Ther 80 235 245
46. AK Daly 2006 Significance of the minor cytochrome P450 3A isoforms Clin Pharmacokinet 45 13 31
47. YS Lin ALS Dowling SD Quigely FM Farin J Zhang J Lamba EG Schuetz KE Thummel 2002 Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism Mol Pharmacol 62 162 172
48. JM Kovarik HD Sabia J Figueiredo H Zimmermann C Reynolds SC Dilzer K Lasseter C Rordorf 2001 Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment Clin Pharmacol Ther 70 425 430
49. AM Hoyumpa S Schenker 1991 Is glucuronidation truly preserved in patients with liver disease? Hepatology 13 786 795
50. M Levy Y Caraco G Geisslinger 1998 Drug acetylation in liver disease Clin Pharmacokinet 34 219 226
51. HJ Shull GR Wilkinson R Johnson 1976 Normal disposition of oxazepam in acute viral hepatitis and cirrhosis Ann Intern Med 84 420 425
52. JW Kraus PV Desmond JP Marshall 1978 Effects of aging and liver disease on disposition of lorazepam Clin Pharmacol Ther 24 411 419
53. H Ghabrial PV Desmond KJ Watson 1986 The effects of age and chronic liver disease on the elimination of temazepam Eur J Clin Pharmacol 30 93 97
54. U Klotz KH Antonin H Brügel PR Bieck 1977 Disposition of diazepam and its major metabolite desmethyldiazepam in patients with liver disease Clin Pharmacol Ther 21 430 436
55. HS Debinski CS Lee JA Danks PI Mackenzie PV Desmond 1995 Localization of 5′-diphosphate-glucuronosyltransferase in human liver injury Gastroenterology 108 1464 1469
56. JX Mazoit P Sandouk JM Scherrmann A Roche 1990 Extrahepatic metabolism of morphine occurs in humans Clin Pharmacol Ther 48 613 618
57. B Crotty KJ Watson PV Desmond 1989 Hepatic extraction of morphine is impaired in cirrhosis Eur J Clin Pharmacol 36 501 506
58. JI Macdonald SM Wallace V Mahachai 1992 Both phenolic and acyl glucuronidation pathways of diflunisal are impaired in patients with liver cirrhosis Eur J Clin Pharmacol 42 471 474
59. M Hildebrand A Hellstern M Humpel 1990 Plasma levels and urinary excretion of lormetazepam in patients with liver cirrhosis and in healthy volunteers Eur J Drug Metab Pharmacokinet 15 19 26
60. J Sonne PB Anderson S Loft M Dossing F Andreasen 1990 Glucuronidation of oxazepam is not spared in patients with hepatic encephalopathy Hepatology 11 951 956
61. P Marcellin F de Bony C Garret C Altman V Boige C Castelnau C Laurent-Puig JC Trinchet P Rolan C Chen JP Mamet R Bidault 2001 Influence of cirrhosis on lamotrigine pharmacokinetics Br J Clin Pharmacol 51 410 414
62. AM Taburet S Naveau G Zorza 1990 Pharmacokinetics of zidovudine in patients with liver cirrhosis Clin Pharmacol Ther 47 731 739
63. G Parker R Bullingham B Kamm 1996 Pharmacokinetics of oral mycophenolate mofetil in volunteer subjects with varying degrees of hepatic oxidative impairment J Clin Pharmacol 36 332 344
64. V Furlan S Demirdjian O Bourdon J Magdalou A-M Taburet 1999 Glucuronidation of drugs by hepatic microsomes derived from healthy and cirrhotic human livers J Pharmacol Exp Ther 289 1169 1175
65. M Congiu ML Mashford JL Slavin PV Desmond 2002 UDP glucuronosyltransferase mRNA levels in human liver disease Drug Metab Disp 30 129 134
66. MJ Zamek-Gliszczynski KA Hofmaster K Nezasa MN Tallman KL Brouwer 2006 Integration of hepatic drug transporters and phase II metabolizing enzymes: mechanisms of hepatic excretion of sulphate, glucuronide and glutathione metabolites Eur J Pharm Sci 27 447 486
67. JL Lam H Okochi Y Huang LZ Benet 2006 In vitro and in vivo correlation of hepatic transporter effects on erythromycin metabolism: characterizing the importance of transporter-enzyme interplay Drug Metab Disp 34 1336 1344
68. CD Klaassen JB Watkins III 1984 Mechanisms of bile formation, hepatic uptake, and biliary excretion Pharmacol Rev 36 1 67
69. PR Mortimer DB Mackie S Haynes 1969 Ampicillin levels in human bile in the presence of biliary tract disease Br Med J 3 88 89
70. JEL Sales M Sutcliffe F O'Grady 1972 Cephalexin levels in human bile in the presence of biliary tract disease Br Med J 3 441 442
71. RB Brown SN Martyak M Barza L Curtis L Weinstein 1976 Penetration of clindamycin phosphate into the abnormal human biliary tract Ann Intern Med 84 168 170
72. JWC Leung RCY Chan SW Cheung JY Sung SCS Chung GL French 1990 The effect of obstruction on the biliary excretion of cefoperazone and ceftazidime J Antimicrob Chemother 25 399 406
73. OM van Delden DJ van Leeuwen PLM Jansen FJ Hoek K Huibregtse GNJ Tytgat 1994 Biliary excretion of ceftriaxon in non-stagnant and stagnant bile J Antimicrob Chemother 33 193 194
74. van den Hazel SJ, de Vries XH, Speelman P, Dankert J, Tytgat GNJ, Huibregtse K, van Leeuwen DJ (1996) Biliary excretion of ciprofloxacin and piperacillin in the obstructed biliary tract. Antimicrob Agents Chemother 40:2658-2660
75. G Zollner P Fickert R Zenz A Fuchsbichler C Stumptner L Kenner P Ferenci RE Stauber GJ Krejs H Denk K Zatloukal M Trauner 2001 Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases Hepatology 33 633 646
76. GA Kullak-Ublick GB Baretton M Oswald EL Renner G Paumgartner U Beuers 2002 Expression of the heaptocyte canalicular multidrug resistant protein (MRP2) in primary biliary cirrhosis Hepatol Res 23 78 82
77. G Zollner P Fickert D Silbert A Fuchsbichler H-U Marschall K Zatloukal M Denk H Tranner 2003 Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis J Hepatol 38 717 727
78. G Gonzales A Aransibia MI Rivas P Caro C Antezana 1982 Pharmacokinetics of frusemide in patients with hepatic cirrhosis Eur J Clin Pharmacol 22 315 320
79. LA Marantonio WHR Auls WR Murdoch R Purohit GG Skellern CA Howes 1983 The pharmacokinetics and pharmacodynamics of the diuretic bumetanide in hepatic and renal disease Br J Clin Pharmacol 25 245 252
80. JP Cello S Oie 1983 Cimetidine disposition in patients with Laennec's cirrhosis during multiple dosing therapy Eur J Clin Pharmacol 25 223 229
81. IL Smith JA Ziemniak H Bernhard FN Eshelman LE Martin JJ Schentagg 1984 Ranitidine disposition and systemic availability in hepatic cirrhosis Clin Pharmacol Ther 35 487 494
82. J Brockmöller T Thomsen M Wittstock R Coupez H Lochs I Roots 2005 Pharmacokinetics of levetiracetam in patients with moderate to severe liver cirrhosis (Child-Pugh classes A, B, and C): characterization by dynamic liver function tests Clin Pharmacol Ther 77 529 541
83. R Orlando M Mussap M Plebani 2002 Diagnostic value of plasma cystatin C as a glomerular filtration marker in decompensated liver cirrhosis Clin Chem 48 850 858
84. NL Proulx A Akbari AX Garg A Rostom J Jaffey HD Clark 2005 Measured creatinine clearance from timed urine collections substantially overestimates glomerular filtration rate in patients with liver cirrhosis: a systematic review and individual patient meta-analysis Nephrol Dial Transplant 20 1617 1622
85. MA Papadakis AI Arieff 1987 Unpredictability of clinical evaluation of renal function in cirrhosis Am J Med 82 945 952
86. GR Granneman G Mahr C Locke P Nickel W Kirch W Fabian M Kinzig KG Naber F Sörgel 1992 Pharmacokinetics of temafloxacin in patients with liver impairment Clin Pharmacokinet 22 Suppl 1 24 32
87. L Caregaro F Menon P Angeli P Amodia C Merkel A Bortoluzzi F Alberino A Gatta 1994 Limitations of serum creatinine level and creatinine clearance as filtration markers in cirrhosis Arch Intern Med 154 201 205
88. B Caujolle F Ballet R Poupon 1988 Relationships among beta-adrenergic blockade, propranolol concentration, and liver function in patients with cirrhosis Scand J Gastroenterol 23 925 930
89. MJ Ramond E Comoy D Lebrec 1986 Alterations in isoprenaline sensitivity in patients with cirrhosis: evidence of abnormality of the sympathetic nervous activity Br J Clin Pharmacol 21 191 196
90. AL Gerbes J Remien D Jungst Y Sauerbruch G Paumgartner 1986 Evidence for down-regulation of beta-2-adrenoceptors in cirrhosis patients with severe cirrhosis Lancet 1 1409 1411
91. I Janku F Perlik M Tkaczykova M Brodanova 1992 Disposition kinetics and concentration-effect relationship of metipranolol in patients with cirrhosis and healthy subjects Eur J Clin Pharmacol 42 337 340
92. E Keller G Hoppe-Seyler R Mumm P Schollmeyer 1981 Influence of hepatic cirrhosis and end-stage renal disease on pharmacokinetics and pharmacodynamics of furosemide Eur J Clin Pharmacol 20 27 33
93. JP Villeneuve RK Verbeeck GR Wilkinson RA Branch 1986 Furosemide kinetics and dynamics in cirrhosis Clin Pharmacol Ther 40 14 20
94. MT Dao JP Villeneuve 1988 Kinetics and dynamics of triamterene at steady-state in patients with cirrhosis Clin Invest Med 11 6 9
95. JP Villeneuve F Rocheleau G Raymond 1984 Triamterene kinetics and dynamics in cirrhosis Clin Pharmacol Ther 35 831 837
96. S Schwartz DC Brater D Pound PK Green WG Kramer D Rudy 1993 Bioavailability, pharmacokinetics and pharmacodynamics of torasemide in patients with cirrhosis Clin Pharmacol Ther 54 90 97
97. P Gentilini G La Villa F Marra V Carloni L Melani M Foschi G Cotrozzi M Quartini G Chibbaro AC Tommassi A Bernareggi A Simoni G Buzzelli G Laffi 1996 Pharmacokinetics and pharmacodynamics of torasemide and furosemide in patients with diuretic resistant ascites J Hepatol 25 481 490
98. LA Marcantonio WHR Auld WR Murdoch R Purohit GG Skellern CA Howes 1983 The pharmacokinetics and pharmacodynamics of the diuretic bumetanide in hepatic and renal disease Br J Clin Pharmacol 15 245 252
99. G Bakti HU Fisch G Karlaganis C Minder J Bircher 1987 Mechanism of the excessive sedative response of cirrhotics to benzodiazepines: model experiments with triazolam Hepatology 7 629 638
100. AJ MacGilchrist GG Birnie A Cook G Scobie T Murray G Watkinson MJ Brodie 1986 Pharmacokinetics and pharmacodynamics of intravenous midazolam in patients with severe alcoholic cirrhosis Gut 27 190 195
101. M Davis 2007 Cholestasis and endogenous opioids - liver disease and endogenous opioid pharmacokinetics Clin Pharmacokinet 46 825 850
102. S Ahboucha G Pomier-Layrargues RF Butterworth 2004 Increased brain concentrations of endogenous (non-benzodiazepine) GABA-A receptor ligands in human hepatic encephalopathy Metab Brain Dis 19 241 251
103. P Gines V Arrovo J Rodes 1992 Pharmacotherapy of ascites associated with cirrhosis Drugs 43 316 332
104. J Roussat M Maillard J Nussberger 1999 Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects Clin Pharmacol Ther 66 76 84
105. RN Pugh IM Murray-Lyon JL Dawson MC Pietroni R Williams 1973 Transection of the oesophagus for bleeding oesophageal varices Br J Surg 60 646 649
106. R Wiesner E Edwards R Freeman 2003 Model for end-stage liver disease (MELD) and allocation of donor livers Gasroenterology 124 91 96
107. E Cholongitas L Marelli V Shusang 2006 A systematic review of the performance of the model for end-stage liver disease (MELD) in the setting of liver transplantation Liver Transpl 12 1049 1061
108. J Brockmöller I Roots 1994 Assessment of liver metabolic function Clin Pharmacokinet 27 216 248
109. P Burra A Masier 2004 Dynamic tests to study liver function Eur Rev Med Pharmacol Sci 8 19 21
110. PA Soons A De Boer AF Cohen DD Breimer 1991 Assessment of hepatic blood flow in healthy subjects by continuous infusion of indocyanine green Br J Clin Pharmacol 32 697 704
111. P Faybik H Hetz 2006 Plasma disappearance rate of indocyanine green in liver dysfunction Transplant Proc 38 801 802
112. S Keiding 1987 Hepatic clearance and liver blood flow J Hepatol 4 393 398
113. J Zeeh H Lange J Bosch S Pohl H Loesgen R Eggers M Navasa J Chesta J Bircher 1988 Steady-state extrarenal sorbitol clearance as a measure of hepatic plasma flow Gastroeneterology 95 749 759
114. G Molino P Avagnina G Belforte J Bircher 1998 Assessment of the hepatic circulation in humans: new concepts based on evidence derived from a D-sorbitol clearance method J Lab Clin Med 131 393 405
115. D Fabre F Bressolle R Gomeni O Bouvet A Dubois C Raffanel JC Gris M Galtier 1993 Identification of patients with impaired hepatic drug metabolism using a limited sampling procedure for estimation of phenazone (antipyrine) pharmacokinetic parameters Clin Pharmacokinet 24 333 343
116. E Renner H Wietholtz P Huguenin MJ Arnaud R Preisig 1984 Caffeine: a model compound for measuring liver function Hepatology 4 38 46
117. JF Rogers ML Rocci DB Haughey JS Bertino 2003 An evaluation of the suitability of intravenous midazolam as an in vivo marker for hepatic cytochrome P4503A activity Clin Pharmacol Ther 73 153 158
118. G Engel U Hofmann H Heidemann J Cosme Eichelbaum 1996 Antipyrine as a probe for human oxidative metabolism: identification of the cytochrome P50 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation Clin Pharmacol Ther 59 613 623
119. A Armuzzi M Candelli MA Zocco A Andreoli A De Lorenzo EC Nista L Miele F Cremonini IA Cazzato A Grieco G Gasbarrini A Gasbarrini 2002 Review article: breath testing for human liver assessment Aliment Pharmacol Ther 16 1977 1996
120. JP Villeneuve C Infante-Rivard M Ampelas G Pomier-Layrargues PM Huet D Marleau 1986 Prognostic value of the aminopyrine breath test in cirrhotic patients Hepatology 6 928 931
121. M Kinirons D O'Shea RB Kim JD Groopman KE Thummel AJ Wood GR Wilkinson 1999 Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A Clin Pharmacol Ther 66 224 31
122. LP Rivory KA Slaviero JM Hoskins SJ Clarke 2001 The erythromycin breath test for prediction of drug clearance Clin Pharmacokinet 40 151 158
123. D Kurnik AJJ Wood GR Wilkinson 2006 The erythromycin breath test reflects P-glycoprotein function indepently of cytochrome P450 3A activity Clin Pharmacol Ther 80 228 234
124. LB Lan JT Dalton EG Schuetz 2000 Mdr1 limits CYP3A metabolism in vivo Mol Pharmacol 58 863 869
125. M Oellerich VW Armstrong 2001 The MEGX test: a tool for the real-time assessment of hepatic function Ther Drug Monit 23 81 92
126. R Orlando P Piccoli S De Martin R Padrini M Floreani P Palatini 2004 Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo Clin Pharmacol Ther 75 80 88
127. YS Huang SD Lee JF Deng JC Xu RH Lu YF Lin Yj Wang KJ Lo 1993 Measuring lidocaine metabolite monoethylglycinexylidide as a quantitative index of hepatic function in adults with chronic hepatitis and cirrhosis J Hepatol 19 140 147
128. B Meyer-Wyss E Renner H Luo A Scholer 1993 Assessment of lidocaine metabolite function in comparison with other quantitative liver function tests J Hepatol 19 133 139
129. S Kawasaki H Immamura Y Bandai K Sanjo Y Idezuki 1992 Direct evidence for the intact hepatocyte theory in patients with liver cirrhosis Gastroenterology 102 1351 1355
130. A Colli G Buccino M Cocciolo R Parravicini G Scaltrini 1988 Disposition of a flow-limited drug (lidocaine) and a metabolic capacity limited drug (theophylline) in liver cirrhosis Clin Pharmacol Ther 44 642 649
131. FDA (2003) Guidance for industry: pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labelling. http://www.fda.gov/cber/gdlns/imphep.pdf. Accessed 16 August 2008
132. EMEA (2005) Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with impaired hepatic function. http://www.emea.europa.eu/pdfs/human/ewp/23390en.pdf. Accessed 16 August 2008
133. JW Spray K Willett D Chase R Sindelar S Connelly 2007 Dosage adjustment for hepatic dysfunction based on Child-Pugh scores Am J Health-Syst Pharm 64 690 693
134. Hebert MF (1998) Guide to drug dosage in hepatic disease. In:Holford N (ed) Drug data handbook, 3rd edn. Adis International, Auckland, pp 121-179
135. SI Sokol A Cheng WH Prishman CS Kaza 2000 Cardiovascular drug therapy in patients with hepatic diseases and patients with congestive heart failure J Clin Pharmacol 40 11 30
136. U Klotz 2007 Antiarrhythmics - elimination and dosage considerations in hepatic impairment Clin Pharmacokinet 46 985 996
137. M Davis 2007 Cholestasis and endogenous opioids: liver disease and exogenous pioid pharmacokinetics Clin Pharmacokinet 46 825 850
138. I Tegeder J Lötsch G Geisslinger 1999 Pharmacokinetics of opioids in liver disease Clin Pharmacokinet 37 17 40
139. SM McCabe Q Ma JC Slish LM Catanzaro N Sheth R DiCenzo GD Morse 2008 Antiretroviral therapy - pharmacokinetic considerations in patients with renal or hepatic impairment Clin Pharmacokinet 47 153 172
140. V Rodighiero 1999 Effect of liver disease on pharmacokinetics - an update Clin Pharmacokinet 37 399 431
141. Kashuba ADM, Park JJ, Persky AM, Brouwer KLR (2006) Drug metabolism, transport, and the influence of hepatic disease. In: Burton ME, Shaw LM, Schentag JJ, Evans WE (eds) Applied pharmacokinetics & pharmacodynamics- principles of therapeutic drug monitoring. Lippincott Williams & Wilkins, Philadelphia, pp 121-164
142. L Tchambaz C Schlatter M Jakob A Krâhenbûhl P Wolf S Krâhenbûhl 2006 Dose adaptation of antineoplastic drugs in patients with liver disease Drug Saf 29 509 522